CytoSorbents Corporation
Nasdaq: CTSO
Russell 2000 Component
IndustryCritical care
Headquarters
Princeton, New Jersey
,
USA
ProductsCytoSorb
RevenueUS$ 41.0 Mio. (2020)[1]
Number of employees
160
WebsiteOfficial website

CytoSorbents Corporation is a publicly traded company (NasdaqCM: CTSO) located in Princeton, New Jersey.[2][3][4]

CytoSorbents sells a cytokine adsorbing column ("CytoSorb" which received CE mark approval in 2011[5]) — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.[6][7]

The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns (Toraymyxin), which failed to show significance in a clinical trial for sepsis.[8] The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy.[9] Clinicaltrials.gov is giving an overview over running research projects.[10]

CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency (DARPA) for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins.[11] The US Army awarded the Company a $1.15 million small-business innovation research contract to evaluate the technology in burn and trauma.[12][13]

References

  1. ↑ "CytoSorbents Announces 2020 Financial and Operational Results". cytosorbents.com. 9 March 2021. Retrieved 28 October 2021.
  2. ↑ "CTSO: Summary for CYTOSORBENTS COR- Yahoo! Finance". YAHOO Finance. Retrieved 9 April 2014.
  3. ↑ "CTSO stock quote – CytoSorbents Corporation stock price – NASDAQ.com". NASDAQ. Retrieved 9 April 2014.
  4. ↑ "CTSO SEC Filings". YAHOO. Retrieved 9 April 2014.
  5. ↑ "With EU Regulatory Approval Gained CytoSorbents Corporation (OTCBB: CTSO) One Step Closer to Goal of FDA Regulatory Approval". OTC Equity. Retrieved 9 April 2014.
  6. ↑ Baum, Stephanie (24 May 2013). "Blood purification device for ICU patients seeks to control cytokine storm". Med City News. Retrieved 2013-05-24.
  7. ↑ "Septic shock secondary to β-hemolytic streptococcus-induced necrotizing fasciitis treated with a novel cytokine adsorption therapy". The International Journal of Artificial Organs. Retrieved 6 May 2014.
  8. ↑ "Spectral Medical's Toraymyxin fails pivotal trial". MassDevice. 3 October 2016. Retrieved 2020-02-28.
  9. ↑ https://literature.cytosorb.com/
  10. ↑ "CTG Labs - NCBI".
  11. ↑ "DARPA Dialysis-Like-Therapeutic Program Awards $3.8M to CytoSorbents". Global BioDefense. 7 August 2012. Retrieved 9 April 2014.
  12. ↑ "CTSO Awarded Ph II U.S. Army Grant". Zacks. Retrieved 9 April 2014.
  13. ↑ "CytoSorbents Corporation". Growjo. Retrieved 19 November 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.